| [Objective] To explore the effect and afety of recombinant human thrombopoietin in promoting blood platelet recovery after allo-hematopoietic stem cell transplantation. [Method] rHuTPO 300 U/kg/d have been hypodermic given to 48 patients accepted allo-HSCT treatment during April 2006 to April 2007 in multicenter for continuing 14 days from day 1 after allo- hematopoietic stem cell transplantation,while nothing has been given to the random contrast 48 patients. [Result] The result of effect: PLT recovered after HSCT at d 17.17±6.96 in the experimental group,as well as d 19.10±10.03 in the control group(P=0.274>0.05);the mean rank of the units of PLT transfusion before recovery is 42.70 in the experimental group,as well as 54.30 in the control group(P=0.040 <0.05). The result of safety:P value of the two groups is 0.441 on ALT,while 0.859 on TBIL,0.232 on BUN and 0.085 on Cr(P >0.05).P value of the two groups on complications after HSCT is 0.233 on aGVHD and 0.779 on cGVHD(P >0.05).The incidence rate of cytomegalovirusemia is 33.3% in the experimental group,as well as 35.4% in the control group. (P >0.05).And there's only one person with VOD in all.The relapse rate in a year is 12.5% in the experimental group,while 14.6% in the control group(P=0.076>0.05). The survival rate in a year is 83.5% in the experimental group,while 77.1% in the control group(P=0.442>0.05). [Conclusion] The use of rhuTPO 300U/kg/d hypodermic given consecutively for 14 days from day 1 after allo- hematopoietic stem cell transplantation can decrease the units of plt transfusion,though it cannot promote blood platelet recovery.The drug doesn't damage the Hepatic and renal function.And it shows no harm to the complication after HSCT,including aGVHD,VOD,CMV infection and cGVHD.It does not increse the relapse rate,as well as not decrese the survival rate in one year after HSCT.
|
PDF Full Text Request